Real-world experience and considerations on concomitant caplacizumab and anticoagulation in thrombotic thrombocytopenic purpura

Ann Hematol. 2023 Feb;102(2):457-459. doi: 10.1007/s00277-022-05049-6. Epub 2022 Nov 28.

Authors

Benson Meek¹, Nuti Desai², Donald C Moore³, Thuy Tran¹, Mary Ann Knovich³, Justin Arnall⁴

Affiliations

¹ Specialty Pharmacy Service, Atrium Health, 4400 Golf Acres Drive, Building J Suite B1, Charlotte, NC, USA.
² WakeMed Health and Hospitals, 3000 New Bern Avenue, Raleigh, NC, 27610, USA.
³ Levine Cancer Institute, 1021 Morehead Medical Dr., Charlotte, NC, 28204, USA.
⁴ Specialty Pharmacy Service, Atrium Health, 4400 Golf Acres Drive, Building J Suite B1, Charlotte, NC, USA. jarnall87@gmail.com.

PMID: 36441262
DOI: 10.1007/s00277-022-05049-6

No abstract available

Keywords: Anticoagulation; Caplacizumab; Hematology; Thrombotic thrombocytopenic purpura.

Publication types

Letter

MeSH terms

ADAMTS13 Protein
Anticoagulants / therapeutic use
Fibrinolytic Agents / therapeutic use
Humans
Plasma Exchange
Purpura, Thrombotic Thrombocytopenic* / complications
Purpura, Thrombotic Thrombocytopenic* / drug therapy
Single-Domain Antibodies* / therapeutic use
von Willebrand Factor

Substances

caplacizumab
Single-Domain Antibodies
von Willebrand Factor
Anticoagulants
ADAMTS13 Protein
Fibrinolytic Agents